大型加州医疗系统中非BRCA遗传性乳腺癌卵巢癌综合征致病性变异携带者的乳腺癌与卵巢癌风险管理
在Kaiser Permanente北加州系统2015年1月1日至2018年12月31日接受HBOC基因检测、随访至2020年3月31日的女性中,非BRCA中风险卵巢致病性变异者的双侧输卵管卵巢切除率与BRCA致病性变异者相似(47.4% vs 54%,p=0.25),但低风险或未知风险者及监测利用均较低,预防策略使用与特定风险一致但整体不足。
要点
- BRCA与非BRCA中风险卵巢致病性变异者的双侧输卵管卵巢切除率相似(47.4% vs 54%,p=0.25)。
- 低风险或未知风险非BRCA致病性变异者的输卵管卵巢切除率分别为12.8%和5.3%,均低于BRCA组(p<0.001)。
- BRCA致病性变异者的双侧乳房切除率为19.7%,高于非BRCA乳腺高风险(10.1%,p=0.028)、中风险(7.7%,p<0.001)和未知风险(0.4%,p<0.001)组。
核心结论
- HBOC致病性变异者的手术和监测策略利用不足,但非BRCA致病性变异者的预防策略使用与特定风险一致。
研究设计与样本
- 在Kaiser Permanente北加州系统对2015年1月1日至2018年12月31日接受HBOC基因检测的女性进行影像学和预防性手术的检查,随访至2020年3月31日。
- 共识别13,271次包含HBOC基因的检测。
主要发现
- 基因检测后双侧输卵管卵巢切除率在BRCA与非BRCA中风险卵巢致病性变异者间相似(47.4% vs 54%,p=0.25)。
- 低风险或未知风险非BRCA致病性变异者的双侧输卵管卵巢切除率分别为12.8%(p<0.001)和5.3%(p<0.001)。
- 第一年卵巢癌监测超声和CA 125使用率:BRCA致病性变异者为63.3%和64.7%,非BRCA中风险致病性变异者为37.5%和27.1%,低风险致病性变异者为13.7%和4.6%。
- 双侧乳房切除率:BRCA致病性变异者19.7%,非BRCA乳腺高风险致病性变异者10.1%(p=0.028),中风险致病性变异者7.7%(p<0.001),未知风险致病性变异者0.4%(p<0.001)。
- 第一年MRI监测率:非BRCA BRCA致病性变异者47.4%,乳腺高风险致病性变异者43%,中风险致病性变异者39.4%,未知风险致病性变异者4.9%。
临床怎么用
- 原文结论指出HBOC致病性变异者的手术和监测策略利用不足,但非BRCA致病性变异者的预防策略使用与特定风险一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe breast and ovarian cancer risk reduction strategies in the clinical management of women who test positive for non-BRCA hereditary breast and ovarian cancer (HBOC) pathogenic variants compared to those who test positive for pathogenic BRCA variants or have negative germline panel testing. METHODS: Examination of imaging and preventive surgeries in women undergoing HBOC genetic testing from 1/1/2015 to 12/31/2018, with follow up to 03/31/2020 in Kaiser Permanente Northern California. RESULTS: A total of 13,271 tests which included HBOC genes were identified. Rate of bilateral salpingo-oophorectomy after genetic testing were similar for BRCA and the non-BRCA moderate risk ovarian pathogenic variants (PVs) (47.4% vs 54%, p = 0.25). Rates were lower for low risk or unknownrisk non-BRCA PVs (12.8%, p < 0.001, 5.3% (p < 0.001). Rates of surveillance for ovarian cancer with ultrasound and CA 125 in the first year was 63.3% and 64.7% for BRCA PV, 37.5% and 27.1%, for non-BRCA moderate risk PVs and 13.7% and 4.6%, for low-risk PVs. Bilateral mastectomy rates were 19.7% for BRCA PV, 10.1% (p = 0.028) for non-BRCA breast high risk PVs, for moderate risk PVs 7.7% (p < 0.001) and for unknown risk 0.4% (p < 0.001). MRI surveillance rates in the first year similarly were 47.4% for non-BRCA BRCA PV, 43% for breast high risk PV, 39.4% for moderate risk and 4.9% for unknown risk PV. CONCLUSION: Surgical and surveillance strategies are underutilized for HBOC PV, however there is concordance of uptake of preventive strategies with specific risk associated with non-BRCA PVs.
引用
- Powell CB, Laurent C, Garcia C, et al. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system. Gynecol Oncol. 2022. PMID: 36220669. doi:10.1016/j.ygyno.2022.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。